GlassScriptPhysician profile
Meredith B Carter
NPI 1770080616
$2,985.65
in general payments reported to CMS, 2019-2025
24 companies · $13.80 in 2025
The $13.80 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,067 · 2022: $509 · 2023: $693 · 2024: $703 · 2025: $13.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $994.34 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $293.67 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $229.99 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $199.20 | 2021-2024 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $196.89 | 2021 | |
| Amgen INC. | $175.36 | 2021-2024 | Otezla, Repatha |
| Pfizer INC. | $124.48 | 2021-2024 | |
| Abbvie INC. | $123.30 | 2021-2024 | |
| Horizon Therapeutics Plc | $105.70 | 2021-2022 | |
| Astellas Pharma US INC | $65.40 | 2021-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $55.78 | 2021-2022 | |
| Exact Sciences Corporation | $51.48 | 2023-2024 | Cologuard Collection Kit |
| Jazz Pharmaceuticals INC. | $49.41 | 2021-2022 | |
| Radius Health, INC. | $47.10 | 2023-2024 | Tymlos |
| Supernus Pharmaceuticals, INC. | $45.52 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $42.33 | 2022 | |
| Idorsia Pharmaceuticals US INC | $36.84 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $33.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.12 | 2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $21.46 | 2021 | |
| Merck Sharp & Dohme LLC | $19.41 | 2024 | Gardasil 9, Gardasil |
| Abbott Laboratories | $18.95 | 2023 | Freestyle Libre 2 |
| Paratek Pharmaceuticals, INC. | $17.49 | 2024 | Nuzyra |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.